11/13/2013
https://congress.gov...
"The foundation laid by Hatch-Waxman Act 30 years ago will continue to be the mechanism by which the management incentives development of lifesaving drugs but we do have an obligation to periodically r..."
"This hearing today has very real implications for patients everywhere. How do we ensure that drug and device companies have the right incentives to discover important new treatments for disease?"
"We cannot rest on our laurels. We have an obligation to periodically reevaluate and adjust to account for the sweeping changes in the health sector."
"Our taxpayers want basic research to be funded through the National Institutes of Health, and I would assume everybody that cares about this problem is outraged when we see cuts at the NIH budget."